Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases

Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage … [Read more…]

3D Has Demanded That Toho HD File Litigation and Thereby Presented Legal Issues in Order to Make the Investigation by the Third-party Committee More Effective

TOKYO–(BUSINESS WIRE)–3D Investment Partners Pte. Ltd. (together with the Fund, “3D” or the “Company”) provides discretionary investment management services to an investment fund which is a shareholder of Toho Holdings Co., Ltd. (TOKYO: 8129, “Toho HD”) (collectively referred to “3D” or “we” together with the investment fund) sent an open letter to the outside directors … [Read more…]

Cosan Secures Strategic Growth Investment to Scale AI-Enabled, Team-Based Virtual Care for Chronic Conditions

CHICAGO–(BUSINESS WIRE)–Cosan, a connected chronic care management company helping providers extend care beyond the clinic, today announced a $15 million strategic growth equity investment led by Ziegler Link-age Funds and Specialty Alliance, the nation’s largest provider of specialty care and a long-standing Cosan partner. The investment accelerates Cosan’s expansion of its AI-enabled, human-led virtual care … [Read more…]

FemHealth Ventures Closes Oversubscribed $65 Million Fund II

SHORT HILLS, N.J.–(BUSINESS WIRE)–#healthcare–FemHealth Ventures, a leading women’s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm’s assets under management to $100 million across two funds and further solidifies FemHealth Ventures’ position as … [Read more…]

Navitus Expands Banjo Health Implementation, Advancing Utilization Management Automation Across Its PBM Platform

MADISON, Wis.–(BUSINESS WIRE)–Navitus, the nation’s first and largest transparent, pass-through pharmacy benefit manager (PBM), today announced the expanded implementation of Banjo Health. Banjo is an advanced automation platform with artificial intelligence (AI) capabilities designed to modernize and simplify prior authorization workflows that are central to pharmacy benefits management. Now implemented across employer and health plan … [Read more…]

Food Industry Accelerates Traceability Ahead of FSMA 204 Deadline

Retailer and Market Demands Drive Rapid Traceability Adoption SALT LAKE CITY–(BUSINESS WIRE)–ReposiTrak (NYSE: TRAK), the industry leader in food traceability and regulatory compliance, announced that the push for traceability is now being driven by market forces rather than federal timelines. During a recent MorningNewsBeat interview, ReposiTrak Chairman and CEO Randy Fields and Affiliated Foods, Inc., … [Read more…]

New Milestone of Hepatitis C Elimination: Taiwan Achieves WHO Goal Ahead of Schedule

TAIPEI, Taiwan–(BUSINESS WIRE)–Taiwan has achieved the World Health Organization’s (WHO) goal of eliminating Hepatitis C by 2025, reaching this milestone ahead of the global timeline. Through cross-sectoral collaboration from central to local levels, the nation has established an integrated strategy covering prevention, screening, and treatment. The results have been outstanding, with all key indicators surpassing … [Read more…]

New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1 Significant improvements in itch were observed as early as … [Read more…]

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing significantly lower rate of annualized asthma exacerbations in patients receiving depemokimab versus placebo SWIFT data included reduction in exacerbations requiring hospitalization and/or emergency department visits with depemokimab An … [Read more…]

insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery

New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth to more rapidly identify novel therapeutic targets SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications … [Read more…]